((自动化翻译由路透提供，请见免责声明 ))
10月17日 - ** Sage Therapeutics公司股价 早盘下跌5.5%，至6.87美元。
** 该公司表示，作为重组计划的一部分，它将裁员 (link)，裁员人数超过165人，其中包括一半以上的研发团队成员。
** 优先推出与百健 联合开发的产后抑郁症药物Zurzuvae和早期实验药物
** 上周，该公司表示，由于在晚期试验中未能达到主要目标，它将停止开发治疗阿尔茨海默病的试验性药物dalzanemdor， (link)。
** 19 家券商的平均建议是 "持有"；中位数 PT 为 10 美元 - LSEG
** 截至上次收盘，该股今年累计下跌66.5%，而纳斯达克生物技术指数 上涨11%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.